Validity and Reliability of the Turkish Version of National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Ovarian Symptom Index-18 (NFOSI-18) and Neurotoxicity-4 (NTX-4) for Patients with Advanced Ovarian Cancer
Table 1
Physical characteristics, disease-related characteristics, and generic health-related quality of life.
n = 94
Mean ± SD or n (%)
Physical characteristics
Age (years)
59.04 ± 9.90
Weight (kg)
70.55 ± 8.46
Height (cm)
161.62 ± 6.97
BMI (kg/m2)
27.08 ± 3.42
Disease-related characteristics
OC subtype
Serous carcinoma (n)
41 (43.6%)
Other (n)
53 (56.4%)
FIGO stage
Stage 2
52 (55.3%)
Stage 3
40 (42.5%)
Stage 4
2 (2.2%)
Received surgery
94 (100%)
Chemotherapy
94 (100%)
Radiotherapy
Yes
48 (51.1%)
No
46 (48.9%)
Follow-up duration since OC diagnosis (months)
52.85 ± 35.25
Generic HRQoL (EQ-5D-3L)
Mobility
1.52 ± 0.50
Self-care
1.23 ± 0.47
Usual activities
1.46 ± 0.59
Pain/discomfort
1.59 ± 0.51
Anxiety/depression
1.61 ± 0.60
EQ-5D-3L total
0.77 ± 0.26
EQ-5D-3L-VAS
74.68 ± 17.45
n: number, SD: standard deviation, %: percentage, BMI: body mass index, kg: kilogram, cm: centimeter, m: meter, OC: ovarian cancer, FIGO: International Federation of Gynecology and Obstetrics, HRQoL: health-related quality of life, EQ-5D: European Quality of Life Survey-5 Dimensions, and VAS: visual analogue scale.
